



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231


RA/L

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/517,545 07/14/00 ARIYASU

T ARTYASU=1A

001444 HM12/1109
BROWDY AND NEIMARK, P.L.L.C.
624 NINTH STREET, NW
SUITE 300
WASHINGTON DC 20001-5303



EXAMINER

KAUFMAN, C

ART UNIT	PAPER NUMBER
----------	--------------

1645

DATE MAILED: 11/09/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

DOCKETED

Amend = 9FE 2002

Office Action Summary

Application No.

09/617,545

Applicant(s)

ARIYASU ET AL.

Examiner

Claire M. Kaufman

Art Unit

1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 10 September 2001.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-16 is/are pending in the application.
- 4a) Of the above claim(s) 8-10, 15 and 16 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-7 and 11-14 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-16 are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 14 July 2000 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☒ Certified copies of the priority documents have been received in Application No. 09/063,778.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 2. 6) ☐ Other:

Art Unit: 1646

DETAILED ACTION

The amendment filed 9/10/01 has been entered.

Election/Restrictions

Applicant's election with traverse of Group I in Paper No. 5 is acknowledged. The traversal is on the ground(s) that examination of plural groups would not involve a serious burden because there is not a serious burden to examine a plurality of groups and one cannot completely search Group I without searching Group II. This is not found persuasive because a search for the full-length encoding nucleic acid is not required for a search of the invention of Group II. The recombinant method producing the encoded protein Group I (*i.e.*, the antigen) does not require searching for anticipatory art for the protein itself, which is not true for the antibody search. Additionally, as previously stated, the different classifications support the need for different searches for each group. Further, the fact that the antibody of Group II may bind to proteins other than human Desert hedgehog, *e.g.*, Sonic hedgehog--see claim 9, means that the search for the antibody requires searches of proteins and/or encoding nucleic acids in addition to human Desert hedgehog, which searches are not required for the DNA claimed. For these reasons, the inventions are distinct.

The requirement is still deemed proper and is therefore made FINAL.

Specification

Applicants are required to use the heading "Brief Description of the Drawings" instead of "Brief Description of the Accompanying Drawings" at page 4. See MPEP 608.01(f).

The disclosure is objected to because of the following informalities: On page 4, fourth line in the paragraph beginning "In FIG. 1," "*coli*;t he" should be ""*coli*; the" .

Appropriate correction is required.

Art Unit: 1646

Claim Objections

Claims 5 and 14 are objected to because of the following informalities: in line 2 of claim 5, "ore" should be --more--; in the last line of claim 14, "Desert" should not be capitalized to be consistent with the rest of the claims. Appropriate correction is required.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 1-5 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. Since the claimed DNA is naturally occurring and is not claimed as purified and/or isolated, the claims do not show the hand of man involved in the invention and, therefore, are unpatentable. See MPEP § 706.03(a) and 2105.

Claim Rejections - 35 USC § 112, Second Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1, 11, 12, 14 and claims 2-7 and 13 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 11 is rejected under 35 U.S.C. 112, second paragraph, as being incomplete for omitting an essential step, such omission amounting to a gap between the steps. See MPEP § 2172.01. The omitted step is: the expression of the DNA. "Allowing" expression does not mean that expression occurs, only that it can occur. "The generated hedgehog protein" is not required to be the one encoded by the DNA which encodes a desert hedgehog protein of human origin. It can instead be an endogenous hedgehog protein, depending on the cell type used.

Art Unit: 1646

Claim 12 is indefinite because it is unclear what a "transformant" is. The specification describes host cells transfected with DNA but is not clear that a "transformant" is limited to a host cell comprising heterologous DNA introduced by transfection or transformation. The claim could be clarified by using phrasing such as "wherein said DNA is expressed through culturing of a host cell transformed by introduction of said DNA which encodes a desert hedgehog protein of human origin".

Claim 12 is also indefinite because 1) it is not clear that the DNA of the last line encodes a human Desert hedgehog protein. If it does not, then there is a gap in steps between making the HuDhh DNA capable of being expressed and getting expression when the DNA expressed encodes a different hedgehog protein. 2) It is not clear which DNA "the DNA" in line 1 is. That is, it is not clear it is said DNA that encodes a desert hedgehog protein of human origin.

Claims 1, 11 and 14 are indefinite because it is unclear what distinguishes a desert hedgehog (Dhh) protein from other proteins, particularly other hedgehog proteins. As a result, the metes and bounds of the claims is not clear. There are no characteristics by which one could distinguish the DNA encoding a Dhh protein of the instant invention from other encoding DNAs. Note that claims 2-4 require only that it contain a part of a specified amino acid sequence. Since a part can be one nucleotide, almost all DNAs comprise at least one nucleotide in common with the sequences listed. For these reasons, the metes and bounds of the claims cannot be determined.

Claim 5 is indefinite because since there is no specified DNA sequence for the DNA of claim 1, one cannot know if the DNA of claim 5 is a different degenerate sequence.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-7 and 11-14 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a DNA comprising SEQ ID NO:5 or 6 or encodes a

Art Unit: 1646

protein comprising the sequence of SEQ ID NO:2 or 3 (*i.e.*, a degenerate DNA), does not reasonably provide enablement for a DNA that is not one of the above but which must still encode a hedgehog or desert hedgehog protein. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

The specification teaches DNA encoding a mature and full-length form (SEQ ID NO: 5 and 6, respectively) of the human desert hedgehog protein of SEQ ID NO:2 and 3. Also taught are partial encoding DNA sequences (SEQ ID NO:4, 8-10) and primers used for PCR amplification, with SEQ ID NO:4 encoding a fragment of the mature protein and SEQ ID NO:8-10 encoding part of a HuDhh precursor (p. 33, middle). The mature mouse Dhh sequence is 374 amino acids long and over 97% identical to SEQ ID NO:2 of the instant application (Ingham et al., US Patent 5,789,543, see attached "COMPARISON"). Human Dhh of SEQ ID NO:2 is 374 amino acids long. SEQ ID NO:1, encoded by SEQ ID NO:4, is 176 amino acids long. The claims have no functional limitation to allow one skilled in the art to identify the claimed subject matter by anything but sequence relationship or name, which gives great breadth to the claims.

There is no disclosure of a function of the claimed HuDhh. There is no guidance for making a DNA without knowing what it looks like or what it does. The specification does not provide limitations on what portion(s) of a DNA must be the same as SEQ ID NO:5 or what minimum shared sequence identity must be present for DNA to be considered an HuDhh-encoding polynucleotide. Note that the language "contains a part or the whole of ... SEQ ID NO:5" (claim 3), does not provide a structural limitation since a part can be one nucleotide. Because the hh family has not only Dhh but also Shh and Ihh, which share sequence identity and have some shared functions like binding patched receptor, it is not straight forward to say that a protein is a Dhh if there is no structure to distinguish it from a Shh or Ihh protein and a function specific to Dhh and not the other proteins of the hh family. If the DNA cannot be used as a probe which will specifically identify other Dhh-encoding polynucleotides with the exclusion of other hh-encoding polynucleotides and the DNA cannot be used to encode a protein which the skilled artisan could use without undue experimentation, then one would not know how to use the claimed DNA. For these reasons, it would require undue experimentation to practice the claimed invention.

Art Unit: 1646

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1-5 are rejected under 35 U.S.C. 102(a) as being anticipated by Drummond et al. (GenBank Accession No. U59748, also known as BC, cited by Applicants).

Drummond (GenBank Accession No. U59748) teaches part of the nucleic acid encoding human Dhh and the corresponding deduced amino acid sequence. The sequence isolated was mRNA, but that shown is DNA. This nucleic acid encodes a human Dhh protein, though not the full-length or mature form of SEQ ID NO:2 or 3 taught in the instant application. Note that the neither the claims nor the specification have a limitation that the Dhh protein of the instant specification must encode a full-length or functional protein.

Prior Art

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Epstein et al. (C, US Patent 5,759,811) describe a single mutation in human Shh associated with tumorigenicity, the existence of a partial nucleic acid sequence of human Dhh and the desire to test hedgehog proteins besides Shh for the ability to promote tumor growth. Ingham et al. (B, US Patent 5,844,079) teach mouse Desert hedgehog (Dhh, SEQ ID NO:9), mouse and human Indian hedgehog (Ihh, SEQ ID NO: 14 and 10, respectively), and mouse, chicken, human and zebrafish Sonic hedgehog (Shh, SEQ ID NO: 11, 8, 13 and 12, respectively). Ingham et al. (US Patent 5,789,543) teaches mouse Dhh (SEQ ID NO:4). No full-length DNA encoding a Dhh protein of human origin appears in the prior art.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Claire M. Kaufman, whose telephone number is (703) 305-5791. Dr. Kaufman can generally be reached Monday through Thursday from 8:30AM to 12:30PM.


Art Unit: 1646

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached at (703) 308-6564.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Official papers filed by fax should be directed to (703) 308-4242. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294. NOTE: If applicant *does* submit a paper by fax, the original signed copy should be retained by the applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office. **Please** advise the examiner at the telephone number above before facsimile transmission.

Claire M. Kaufman, Ph.D.



Patent Examiner, Art Unit 1646

November 7, 2001

; Patent No. 5789543: COMPARISON TO SEQ ID NO:2

; APPLICANT: Ingham, Phillip W.

APPLICANT: McMahon, Andrew P.

APPLICANT: Tabin, Clifford J.

7 TITLE OF INVENTION: Vertebrate Embryonic Pattern-Inducing

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
84

; CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/176,427B

FILING DATE: 30-DEC-1993

; INFORMATION FOR SEQ ID NO: 4:

; SEQUENCE CHARACTERISTICS:

LENGTH: 396 amino acids

; TYPE: amino acid

```

;      TOPOLOGY:  linear

```

; MOLECULE TYPE: protein

Query Match 97.6%; Score 1761; DB 2; Length 396;
Best Local Similarity 97.3%; Pred. No. 1.9e-191;
Matches 364; Conservative 9; Mismatches 1; Indels 0; Gaps 0;

Qy 1 CGPGRGPVGRRRYARKQLVPLLYKQFVPGVPERTLGASGPAEGRVARGSERFRDLVPNYN 60
| | | | | : | | | | | : | | | | |
Db 23 CGPGRGPVGRRRYVRKQLVPLLYKQFVPSMPERTLGASGPAEGRVTRGSEFRDLVPNYN 82

Qy 61 PDIIFKDEENSGADRLMTERCKERVNALAIAVMMNMPGVRLRVTEGWDEDGHHAQDSLHY 120
 |||||
 Db 83 PDIIFKDEENSGADRLMTERCKERVNALAIAVMMNMPGVRLRVTEGWDEDGHHAQDSLHY 142

QY 121 EGRALDITTSDRDRNKYGLLARLAVEAGFDWVYYESRNHIHVSVKADNSLAVRAGGCFPG 180
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 143 EGRALDITTSDRDRNKYGLLARLAVEAGFDWVYYESRNHIHVSVKADNSLAVRAGGCFPG 202

QY 181 NATVRLWSGERKGLRELHRGDWVLTDASGRVVPTPVLLFLDRDLQRRASFVAVETEWPP 240
| | | | : | | | | | | | | | | : | | : | | | | | | | | | | | | | | | | : | |
Db 203 NATVRLRSGERKGLRELHRGDWVLAADAAGRNVPTPVLLFLDRDLQRRASFVAVETERPP 262

QY 241 RKLLLT²⁴¹ PWHLVFAARGPAPAGDFAPVFARRLRAGDSVLAPGGDALRPARVARVAREEAV 300
 |||||²⁴² |||||²⁴³ |||||²⁴⁴ |||||²⁴⁵ |||||²⁴⁶ |||||²⁴⁷ |||||²⁴⁸ |||||²⁴⁹ |||||²⁵⁰ |||||²⁵¹ |||||²⁵² |||||²⁵³ |||||²⁵⁴ |||||²⁵⁵ |||||²⁵⁶ |||||²⁵⁷ |||||²⁵⁸ |||||²⁵⁹ |||||²⁶⁰ |||||²⁶¹ |||||²⁶² |||||²⁶³ |||||²⁶⁴ |||||²⁶⁵ |||||²⁶⁶ |||||²⁶⁷ |||||²⁶⁸ |||||²⁶⁹ |||||²⁷⁰ |||||²⁷¹ |||||²⁷² |||||²⁷³ |||||²⁷⁴ |||||²⁷⁵ |||||²⁷⁶ |||||²⁷⁷ |||||²⁷⁸ |||||²⁷⁹ |||||²⁸⁰ |||||²⁸¹ |||||²⁸² |||||²⁸³ |||||²⁸⁴ |||||²⁸⁵ |||||²⁸⁶ |||||²⁸⁷ |||||²⁸⁸ |||||²⁸⁹ |||||²⁹⁰ |||||²⁹¹ |||||²⁹² |||||²⁹³ |||||²⁹⁴ |||||²⁹⁵ |||||²⁹⁶ |||||²⁹⁷ |||||²⁹⁸ |||||²⁹⁹ |||||³⁰⁰ |||||³⁰¹ |||||³⁰² |||||³⁰³ |||||³⁰⁴ |||||³⁰⁵ |||||³⁰⁶ |||||³⁰⁷ |||||³⁰⁸ |||||³⁰⁹ |||||³¹⁰ |||||³¹¹ |||||³¹² |||||³¹³ |||||³¹⁴ |||||³¹⁵ |||||³¹⁶ |||||³¹⁷ |||||³¹⁸ |||||³¹⁹ |||||³²⁰ |||||³²¹ |||||³²² |||||³²³ |||||³²⁴ |||||³²⁵ |||||³²⁶ |||||³²⁷ |||||³²⁸ |||||³²⁹ |||||³³⁰ |||||³³¹ |||||³³² |||||³³³ |||||³³⁴ |||||³³⁵ |||||³³⁶ |||||³³⁷ |||||³³⁸ |||||³³⁹ |||||³⁴⁰ |||||³⁴¹ |||||³⁴² |||||³⁴³ |||||³⁴⁴ |||||³⁴⁵ |||||³⁴⁶ |||||³⁴⁷ |||||³⁴⁸ |||||³⁴⁹ |||||³⁵⁰ |||||³⁵¹ |||||³⁵² |||||³⁵³ |||||³⁵⁴ |||||³⁵⁵ |||||³⁵⁶ |||||³⁵⁷ |||||³⁵⁸ |||||³⁵⁹ |||||³⁶⁰ |||||³⁶¹ |||||³⁶² |||||³⁶³ |||||³⁶⁴ |||||³⁶⁵ |||||³⁶⁶ |||||³⁶⁷ |||||³⁶⁸ |||||³⁶⁹ |||||³⁷⁰ |||||³⁷¹ |||||³⁷² |||||³⁷³ |||||³⁷⁴ |||||³⁷⁵ |||||³⁷⁶ |||||³⁷⁷ |||||³⁷⁸ |||||³⁷⁹ |||||³⁸⁰ |||||³⁸¹ |||||³⁸² |||||³⁸³ |||||³⁸⁴ |||||³⁸⁵ |||||³⁸⁶ |||||³⁸⁷ |||||³⁸⁸ |||||³⁸⁹ |||||³⁹⁰ |||||³⁹¹ |||||³⁹² |||||³⁹³ |||||³⁹⁴ |||||³⁹⁵ |||||³⁹⁶ |||||³⁹⁷ |||||³⁹⁸ |||||³⁹⁹ |||||⁴⁰⁰ |||||⁴⁰¹ |||||⁴⁰² |||||⁴⁰³ |||||⁴⁰⁴ |||||⁴⁰⁵ |||||⁴⁰⁶ |||||⁴⁰⁷ |||||⁴⁰⁸ |||||⁴⁰⁹ |||||⁴¹⁰ |||||⁴¹¹ |||||⁴¹² |||||⁴¹³ |||||⁴¹⁴ |||||⁴¹⁵ |||||⁴¹⁶ |||||⁴¹⁷ |||||⁴¹⁸ |||||⁴¹⁹ |||||⁴²⁰ |||||⁴²¹ |||||⁴²² |||||⁴²³ |||||⁴²⁴ |||||⁴²⁵ |||||⁴²⁶ |||||⁴²⁷ |||||⁴²⁸ |||||⁴²⁹ |||||⁴³⁰ |||||⁴³¹ |||||⁴³² |||||⁴³³ |||||⁴³⁴ |||||⁴³⁵ |||||⁴³⁶ |||||⁴³⁷ |||||⁴³⁸ |||||⁴³⁹ |||||⁴⁴⁰ |||||⁴⁴¹ |||||⁴⁴² |||||⁴⁴³ |||||⁴⁴⁴ |||||⁴⁴⁵ |||||⁴⁴⁶ |||||⁴⁴⁷ |||||⁴⁴⁸ |||||⁴⁴⁹ |||||⁴⁵⁰ |||||⁴⁵¹ |||||⁴⁵² |||||⁴⁵³ |||||⁴⁵⁴ |||||⁴⁵⁵ |||||⁴⁵⁶ |||||⁴⁵⁷ |||||⁴⁵⁸ |||||⁴⁵⁹ |||||⁴⁶⁰ |||||⁴⁶¹ |||||⁴⁶² |||||⁴⁶³ |||||⁴⁶⁴ |||||⁴⁶⁵ |||||⁴⁶⁶ |||||⁴⁶⁷ |||||⁴⁶⁸ |||||⁴⁶⁹ |||||⁴⁷⁰ |||||⁴⁷¹ |||||⁴⁷² |||||⁴⁷³ |||||⁴⁷⁴ |||||⁴⁷⁵ |||||⁴⁷⁶ |||||⁴⁷⁷ |||||⁴⁷⁸ |||||⁴⁷⁹ |||||⁴⁸⁰ |||||⁴⁸¹ |||||⁴⁸² |||||⁴⁸³ |||||⁴⁸⁴ |||||⁴⁸⁵ |||||⁴⁸⁶ |||||⁴⁸⁷ |||||⁴⁸⁸ |||||⁴⁸⁹ |||||⁴⁹⁰ |||||⁴⁹¹ |||||⁴⁹² |||||⁴⁹³ |||||⁴⁹⁴ |||||⁴⁹⁵ |||||⁴⁹⁶ |||||⁴⁹⁷ |||||⁴⁹⁸ |||||⁴⁹⁹ |||||⁵⁰⁰ |||||⁵⁰¹ |||||⁵⁰² |||||⁵⁰³ |||||⁵⁰⁴ |||||⁵⁰⁵ |||||⁵⁰⁶ |||||⁵⁰⁷ |||||⁵⁰⁸ |||||⁵⁰⁹ |||||⁵¹⁰ |||||⁵¹¹ |||||⁵¹² |||||⁵¹³ |||||⁵¹⁴ |||||⁵¹⁵ |||||⁵¹⁶ |||||⁵¹⁷ |||||⁵¹⁸ |||||⁵¹⁹ |||||⁵²⁰ |||||⁵²¹ |||||⁵²² |||||⁵²³ |||||⁵²⁴ |||||⁵²⁵ |||||⁵²⁶ |||||⁵²⁷ |||||⁵²⁸ |||||⁵²⁹ |||||⁵³⁰ |||||⁵³¹ |||||⁵³² |||||⁵³³ |||||⁵³⁴ |||||⁵³⁵ |||||⁵³⁶ |||||⁵³⁷ |||||⁵³⁸ |||||⁵³⁹ |||||⁵⁴⁰ |||||⁵⁴¹ |||||⁵⁴² |||||⁵⁴³ |||||⁵⁴⁴ |||||⁵⁴⁵ |||||⁵⁴⁶ |||||⁵⁴⁷ |||||⁵⁴⁸ |||||⁵⁴⁹ |||||⁵⁵⁰ |||||⁵⁵¹ |||||⁵⁵² |||||⁵⁵³ |||||⁵⁵⁴ |||||⁵⁵⁵ |||||⁵⁵⁶ |||||⁵⁵⁷ |||||⁵⁵⁸ |||||⁵⁵⁹ |||||⁵⁶⁰ |||||⁵⁶¹ |||||⁵⁶² |||||⁵⁶³ |||||⁵⁶⁴ |||||⁵⁶⁵ |||||⁵⁶⁶ |||||⁵⁶⁷ |||||⁵⁶⁸ |||||⁵⁶⁹ |||||⁵⁷⁰ |||||⁵⁷¹ |||||⁵⁷² |||||⁵⁷³ |||||⁵⁷⁴ |||||⁵⁷⁵ |||||⁵⁷⁶ |||||⁵⁷⁷ |||||^{578</}

Qy 301 GVFPALTAHGTLNVNDVLASCYAVLESHQWAHRAFAPLRLLHALGALLPGGAVQPTGMHW 360
 |||||
 Db 323 GVFPALTAHGTLNVNDVLASCYAVLESHQWAHRAFAPLRLLHALGALLPGGAVQPTGMHW 382

Qy 361 YSRLLYRLAEELG 374
 | | | | | | | | | | : |

Db 383 YSRLLYRLAEELMG 396

BEST AVAILABLE COPY